22.04.2022 13:15:14
|
Novavax Administers First Doses Of COVID-19 Vaccine Booster In Adolescents In Phase 3 Trial
(RTTNews) - Biotechnology company Novavax, Inc. (NVAX) announced Friday that it has initiated administration of the first booster doses of NVX-CoV2373, the company's protein-based COVID-19 vaccine, in the pediatric expansion of the PREVENT-19 pivotal Phase 3 clinical trial.
The study will evaluate the safety and immunogenicity of a third dose of NVX-CoV2373 among trial participants aged 12 through 17.
All PREVENT-19 trial participants aged 12 through 17 are now eligible to receive a third booster dose of NVX-CoV2373.
The booster dose is identical to the active vaccine previously administered to the participants in a two-dose regimen (5 micrograms of recombinant spike protein plus 50 micrograms of Matrix-M adjuvant) and may be administered at least five months after receipt of active vaccine.
Post-booster objectives include the assessment of the humoral immune response 28 days after the administration of the booster dose, as well as describing COVID-19 disease. Initial results are expected during the second half of 2022.
NVX-CoV2373 has not yet been authorized for use in the U.S. by the U.S. Food and Drug Administration.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novavax Inc.mehr Nachrichten
26.02.25 |
Ausblick: Novavax vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
11.11.24 |
Ausblick: Novavax präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) |
Analysen zu Novavax Inc.mehr Analysen
Aktien in diesem Artikel
Novavax Inc. | 7,48 | 2,16% |
|